Case for the wider adoption of mass spectrometry-based adrenal steroid testing, and beyond

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 12, 2014, Pages 4434-4437

  Monaghan, Phillip J ^c   Keevil, Brian G ^a   Stewart, Paul M ^b   Trainer, Peter J ^c,d  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CORTISONE; HYDROCORTISONE; METYRAPONE; SEX HORMONE; STEROID; STEROID HORMONE; CORTICOSTEROID;

CALIBRATION; CLINICAL DECISION MAKING; CUSHING SYNDROME; HORMONE DETERMINATION; HUMAN; IMMUNOASSAY; IMMUNOLOGY TEST KIT; MASS SPECTROMETER; MASS SPECTROMETRY; MEDICAL LITERATURE; NOTE; PRACTICE GUIDELINE; QUALITY CONTROL; SEX HORMONE DETERMINATION; STANDARDIZATION; VALIDITY; ADRENAL GLAND DISEASES; BLOOD; FEMALE; MALE; REPRODUCIBILITY; STANDARDS; UTILIZATION;

ADRENAL CORTEX HORMONES; ADRENAL GLAND DISEASES; FEMALE; GONADAL STEROID HORMONES; HUMANS; IMMUNOASSAY; MALE; MASS SPECTROMETRY; REPRODUCIBILITY OF RESULTS;

EID: 84916618597     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2258     Document Type: Note

References (15)

1. Handelsman DJ, Wartofsky L. Requirement for mass spectrometry sex steroid assays in the Journal of Clinical Endocrinology and Metabolism. J Clin Endocrinol Metab. 2013;98:3971-3973.
2. Monaghan PJ, Keevil BG, Trainer PJ. The use of mass spectrometry to improve the diagnosis and the management of the HPA axis. Rev Endocr Metab Disord. 2013;14:143-157.
3. Jeffery J, MacKenzie F, Beckett G, Perry L, Ayling R. Norethisterone interference in testosterone assays. Ann Clin Biochem. 2014;51: 284-288.
4. Dodd AJ, Ducroq DH, Neale SM, et al. The effect of serum matrix and gender on cortisol measurement by commonly used immunoassays. Ann Clin Biochem. 2014;51:379-385.
5. Wieringa G, Naing S, Perry LA, et al. What value do cortisol measurements provide in monitoring metyrapone therapy? Endocr Abstracts. 2002;3:P274.
6. Monaghan PJ, Owen LJ, Trainer PJ, Brabant G, Keevil BG, Darby D. Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11β-hydroxylase inhibitor metyrapone. Ann Clin Biochem. 2011;48:441-446.
7. Verhelst JA, Trainer PJ, Howlett TA, et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin Endocrinol (Oxf). 1991;35:169-178.
8. Bertagna X, Pivonello R, Fleseriu M, et al. LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study. J Clin Endocrinol Metab. 2014;99:1375-1383.
9. Bock JL. The new era of automated immunoassay. Am J Clin Pathol. 2000;113:628-646.
10. Owen LJ, Adaway JE, Davies S, et al. Development of a rapid assay for the analysis of serum cortisol and its implementation into a routine service laboratory. Ann Clin Biochem. 2013;50:345-352.
11. Vogeser M, Seger C. Pitfalls associated with the use of liquid chro-matography- tandem mass spectrometry in the clinical laboratory. Clin Chem. 2010;56:1234-1244.
12. Dybkaer R. Vocabulary for use in measurement procedures and description of reference materials in laboratory medicine. Eur J Clin Chem Clin Biochem. 1997;35(2):141-173.
13. Trufelli H, Palma P, Famiglini G, Cappiello A. An overview of matrix effects in liquid chromatography-mass spectrometry. Mass Spectrom Rev. 2011;30:491-509.
14. Owen LJ, Keevil BG. Testosterone measurement by liquid chromatography tandem mass spectrometry: the importance of internal standard choice. Ann Clin Biochem. 2012;49:600-602.
15. Fraser WD, Milan AM. Vitamin D assays: past and present debates, difficulties, and developments. Calcif Tissue Int. 2013;92:118-127.